Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  2,704 results for ""VASCULAR endothelial growth factors""

Your Filters

Subject : bevacizumab
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Factors Predicting Treatment Response in Anti-Vascular Endothelial Growth Factor Naïve Diabetic Macular Edema Patients Treated with Intravitreal Bevacizumab.

  • Authors : Bezzina AD; Specialist Research Project submitted in partial fulfillment of the requirements for the qualification of Master in Surgery (Ch.M.) in Clinical Ophthalmology offered by the University of Edinburgh.; Department of Ophthalmology, Mater Dei General Hospital, Msida, Malta.

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*pharmacology ; Bevacizumab/Bevacizumab/Bevacizumab/*pharmacology ; Vascular Endothelial Growth Factors/Vascular Endothelial Growth Factors/Vascular Endothelial Growth Factors/*antagonists & inhibitors

  • Source: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics [J Ocul Pharmacol Ther] 2019 Dec; Vol. 35 (10), pp. Publisher: Association For Ocular Pharmacology And Therapeutics Country of Publication: United States NLM ID: 9511091 Publication Model: Print-Electronic

Record details

Read More Add to Saved list
×
Academic Journal

Synergistic anti-tumor effects of bevacizumab and tumor targeted polymerized VEGF siRNA nanoparticles.

  • Authors : Kim MG; Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, 5, Hwarang-ro, 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea; School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon 16410, Republic of Korea.

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacology ; Bevacizumab/Bevacizumab/Bevacizumab/*pharmacology ; Nanoparticles/Nanoparticles/Nanoparticles/*chemistry

  • Source: Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2017 Jul 15; Vol. 489 (1), pp. 35-41. Date of Electronic Publication: 2017 May 19.Publisher: Elsevier Country of Publication: United States NLM ID: 0372516 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways via off-VEGF signaling.

  • Authors : Zhang X; Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.; Zhang Y

Subjects: Bevacizumab/Bevacizumab/Bevacizumab/*pharmacology ; Human Umbilical Vein Endothelial Cells/Human Umbilical Vein Endothelial Cells/Human Umbilical Vein Endothelial Cells/*drug effects ; Indoles/Indoles/Indoles/*pharmacology

  • Source: Cancer biology & medicine [Cancer Biol Med] 2020 May 15; Vol. 17 (2), pp. 418-432.Publisher: Chinese Anti-Cancer Association Country of Publication: China NLM ID: 101588850 Publication Model: Print Cited Medium: Print ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Strong Antitumor Activity of Bevacizumab and Aflibercept in Neuroendocrine Carcinomas: In-Depth Preclinical Study.

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*pharmacology ; Bevacizumab/Bevacizumab/Bevacizumab/*pharmacology ; Carcinoma, Neuroendocrine/Carcinoma, Neuroendocrine/Carcinoma, Neuroendocrine/*drug therapy

  • Source: Neuroendocrinology [Neuroendocrinology] 2020; Vol. 110 (1-2), pp. 50-62. Date of Electronic Publication: 2019 Apr 29.Publisher: Karger Country of Publication: Switzerland NLM ID: 0035665 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1423-0194

Record details

Read More Add to Saved list
×
Academic Journal

Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake.

  • Authors : Ko SY; 1Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas USA.; Lee W

Subjects: Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/*pharmacology ; Bevacizumab/Bevacizumab/Bevacizumab/*pharmacology ; Neovascularization, Pathologic/Neovascularization, Pathologic/Neovascularization, Pathologic/*etiology

  • Source: Communications biology [Commun Biol] 2019 Oct 18; Vol. 2, pp. 386. Date of Electronic Publication: 2019 Oct 18 (Print Publication: 2019).Publisher: Nature Publishing Group UK Country of Publication: England NLM ID: 101719179 Publication Model: eCollection Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Intravitreal Anti-Vascular Endothelial Growth Factor Drugs for Retinal Angiomatous Proliferation in Real-Life Practice.

  • Authors : Parodi MB; 1 Department of Ophthalmology, San Raffaele Hospital, Università Vita e Salute , Milano, Italy .; Donati S

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*therapeutic use ; Bevacizumab/Bevacizumab/Bevacizumab/*therapeutic use ; Choroidal Neovascularization/Choroidal Neovascularization/Choroidal Neovascularization/*drug therapy

  • Source: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics [J Ocul Pharmacol Ther] 2017 Mar; Vol. 33 (2), pp. Publisher: Association For Ocular Pharmacology And Therapeutics Country of Publication: United States NLM ID: 9511091 Publication Model: Print-Electronic

Record details

Read More Add to Saved list
×
Academic Journal

Safety and Effectiveness of Cataract Surgery with Simultaneous Intravitreal Anti-VEGF in Patients with Previously Treated Exudative Age-Related Macular Degeneration.

  • Authors : Falcão MS; Ophthalmology Department. Centro Hospitalar São João. Porto. Portugal.; Department of Sense Organs. Faculdade de Medicina. Universidade do Porto. Porto. Portugal.

Subjects: Cataract Extraction*/Cataract Extraction*/Cataract Extraction*/adverse effects; Bevacizumab/Bevacizumab/Bevacizumab/*administration & dosage ; Cataract/Cataract/Cataract/*drug therapy

  • Source: Acta medica portuguesa [Acta Med Port] 2017 Feb 27; Vol. 30 (2), pp. 127-133. Date of Electronic Publication: 2017 Feb 27.Publisher: Centro Editor Livreiro da Ordem dos Médicos Country of Publication: Portugal NLM ID: 7906803 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Long-Term Outcomes of Anti-Vascular Endothelial Growth Factor Therapy for Polypoidal Choroidal Vasculopathy.

  • Authors : Chang YS; 1 Department of Ophthalmology, Konyang University College of Medicine , Daejeon, South Korea .; Kim JH

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*pharmacology ; Bevacizumab/Bevacizumab/Bevacizumab/*pharmacology ; Choroidal Neovascularization/Choroidal Neovascularization/Choroidal Neovascularization/*drug therapy

  • Source: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics [J Ocul Pharmacol Ther] 2016 May; Vol. 32 (4), pp. Publisher: Association For Ocular Pharmacology And Therapeutics Country of Publication: United States NLM ID: 9511091 Publication Model: Print-Electronic

Record details

Read More Add to Saved list
×
Academic Journal

A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN).

  • Authors : Chakravarthy U; Centre for Experimental Medicine, Institute of Clinical Science, Queen's University Belfast, Belfast, UK.; Harding SP

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*therapeutic use ; Bevacizumab/Bevacizumab/Bevacizumab/*therapeutic use ; Choroidal Neovascularization/Choroidal Neovascularization/Choroidal Neovascularization/*drug therapy

  • Source: Health technology assessment (Winchester, England) [Health Technol Assess] 2015 Oct; Vol. 19 (78), pp. 1-298.Publisher: NIHR Journals Library Country of Publication: England NLM ID: 9706284 Publication Model: Print Cited Medium: Internet ISSN: 2046-4924

Record details

Read More Add to Saved list
×
Academic Journal

Diels-Alder hydrogels with enhanced stability: First step toward controlled release of bevacizumab.

  • Authors : Kirchhof S; Department of Pharmaceutical Technology, Faculty of Chemistry and Pharmacy, University of Regensburg, 93040 Regensburg, Germany.; Gregoritza M

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*chemistry ; Bevacizumab/Bevacizumab/Bevacizumab/*chemistry ; Hydrogels/Hydrogels/Hydrogels/*chemistry

  • Source: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2015 Oct; Vol. 96, pp. Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 9109778 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  2,704 results for ""VASCULAR endothelial growth factors""